KDR and B-cell chronic lymphocytic leukemia: In addition to the hypothetical use of VEGFA SNPs to predict the clinical outcome for CLL, these polymorphisms could be used as markers of clinical efficacy for chemoimmunotherapy with novel agents targeting VEGF or its receptor (VEGFR) to prevent leukaemia progression [39].